PTNT Stock Price, Chart, Stats & News
Corgi ETF Trust I - Corgi IP Licensing & Royalties ETF (PTNT) does not currently pay a dividend.
PTNT chart
PTNT returns
| 1Y volatility | 0.00% |
| 3Y volatility | 0.00% |
| Sharpe ratio | 0.00 |
About
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases.
Top 10 PTNT holdings
| Holding | Ownership |
|---|---|
Consumer Cyclical 8.13% | |
Technology 6.34% | |
Communication Services 5.73% | |
Technology 5.10% | |
Communication Services 5.08% | |
Health care 4.91% | |
Technology 4.86% | |
Consumer Cyclical 4.78% | |
Technology 4.50% | |
Communication Services 4.33% |
Similar securities
Based on sector and market capitalization
